Piper Sandler on Abivax (ABVX): 'We Remain Buyers'

March 17, 2026 7:54 AM

Piper Sandler analyst Allison M. Bratzel reiterated an Overweight rating and $165.00 price target on Abivax (NASDAQ: ABVX).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found